Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376032 | 1.00 | CTSK (0.47) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL376195 | 1.00 | CTSK (0.47) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL4215161 | 1.00 | CTSK (0.47) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL1147462 | 0.85 | CTSK (0.48) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL11151475 | 0.85 | CTSK (0.48) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL490640 | 0.85 | CTSK (0.48) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL3777346 | 0.84 | CTSK (0.46) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL375995 | 0.84 | CTSK (0.47) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL8689950 | 0.84 | CTSK (0.50) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL1486213 | 0.84 | CTSK (0.50) | CTSKCTSSHDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-2086956-B1 | INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2011-09-14 | — | — | EP | disclosed |
| EP-2297128-A1 | INHIBITORS OF IKK- SERINE-THREONINE PROTEIN KINASE | Chroma Therapeutics Ltd. (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-17 | — | — | US | disclosed |
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | IKBKB, IKBKE, CHUK | CTSK 2888/4885CTSS 2844/4885HDAC4 2279/4885 |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CSNK1E, PACSIN2, CHUK | CTSK 840/4885CTSS 1123/4885HDAC4 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.